🟢 GT Biopharma is trading 10.90% up in pre-market after Nasdaq disclosed a planned 1-for-25 reverse split

GT Biopharma is trading 10.90% up in pre-market at $0.28 after Nasdaq disclosed a planned 1-for-25 reverse stock split.

• The reverse split becomes effective September 8, 2026, with a new CUSIP number.
• The corporate action is the clearest company-specific catalyst after September 3’s 10.81% decline.
• No new earnings, clinical, regulatory, or financing announcement was identified; pre-market volume data is unavailable.